IP Library › Granted Patent US 10,550,182
Granted Patent B2
US 10,550,182 · App. 15/677,651 · Granted Feb 4, 2020

T cell receptors and immune therapy using the same

Inventors: Leonie Alten (Tübingen, DE); Dominik Maurer (Moessingen, DE); Steffen Walter (Houston, TX); Sebastian Bunk (Tübingen, DE)
Assignee: Immatics Biotechnologies GmbH
C07K16/2803A61P35/00C07K14/7051C07K14/78C07K16/18A61K39/00A61K2039/505C07K2317/32C07K2317/92C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,550,182
App. No.
15/677,651
Granted
Feb 4, 2020
Kind
B2
Abstract

The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Claims (83)

1. A single chain TCR comprising the amino acid sequences of

(a) SEQ ID NOs: 1, 2, 3, 7, 8, and 9; or

(b) SEQ ID NOs: 13, 14, 15, 19, 20, and 21, or

(c) SEQ ID NOs: 25, 26, 27, 31, 32, and 33.

2. The single chain TCR of claim 1 , wherein the TCR variable chain region consists of the amino acid sequence of SEQ ID NO: 4.

3. The single chain TCR of claim 1 , comprising

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 1,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 2,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 3,

a CDR1β chain comprising the amino acid sequences of SEQ ID NO: 7,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 8, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 9; or

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 13,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 14,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 15,

a CDR1β chain comprising the amino acid sequences of SEQ ID NO: 19,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 20, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 21; or

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 25,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 26,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 27,

a CDR1β chain comprising the amino acid sequence of SEQ ID NO: 31,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 32, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 33.

4. The single chain TCR of claim 1 , comprising

a CDR1α chain consisting of the amino acid sequence of SEQ ID NO: 1,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 2,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 3,

a CDR1β chain consisting of the amino acid sequences of SEQ ID NO: 7,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 8, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 9; or

a CDR1α chain consisting of the amino acid sequence of SEQ ID NO: 13,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 14,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 15,

a CDR1β chain consisting of the amino acid sequences of SEQ ID NO: 19,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 20, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 21; or

a CDR1α chain consisting of the amino acid sequence of SEQ ID NO: 25,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 26,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 27,

a CDR1β chain consisting of the amino acid sequence of SEQ ID NO: 31,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 32, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 33.

5. The single chain TCR of claim 1 , comprising

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 1,

a CDR2α chain consisting of the amino acid sequence of SEQ ID NO: 2,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 3,

a CDR1β chain comprising the amino acid sequences of SEQ ID NO: 7,

a CDR2β chain consisting of the amino acid sequence of SEQ ID NO: 8, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 9; or

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 13,

a CDR2α chain consisting of the amino acid sequence of SEQ ID NO: 14,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 15,

a CDR1β chain comprising the amino acid sequences of SEQ ID NO: 19,

a CDR2β chain consisting of the amino acid sequence of SEQ ID NO: 20, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 21; or

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 25,

a CDR2α chain consisting of the amino acid sequence of SEQ ID NO: 26,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 27,

a CDR1β chain comprising the amino acid sequence of SEQ ID NO: 31,

a CDR2β chain consisting of the amino acid sequence of SEQ ID NO: 32, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 33.

6. The single chain TCR of claim 1 , comprising

a CDR1α chain consisting of the amino acid sequence of SEQ ID NO: 1,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 2,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 3,

a CDR1β chain consisting of the amino acid sequences of SEQ ID NO: 7,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 8, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 9.

7. The single chain TCR of claim 1 , comprising

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 1,

a CDR2α chain consisting of the amino acid sequence of SEQ ID NO: 2,

a CDR3α chain comprising the amino acid sequence of SEQ ID NO: 3,

a CDR1β chain comprising the amino acid sequences of SEQ ID NO: 7,

a CDR2β chain consisting of the amino acid sequence of SEQ ID NO: 8, and

a CDR3β chain comprising the amino acid sequence of SEQ ID NO: 9.

8. The single chain TCR of claim 1 , comprising

a CDR1α chain comprising the amino acid sequence of SEQ ID NO: 1,

a CDR2α chain comprising the amino acid sequence of SEQ ID NO: 2,

a CDR3α chain consisting of the amino acid sequence of SEQ ID NO: 3,

a CDR1β chain comprising the amino acid sequences of SEQ ID NO: 7,

a CDR2β chain comprising the amino acid sequence of SEQ ID NO: 8, and

a CDR3β chain consisting of the amino acid sequence of SEQ ID NO: 9.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2019
From: ALTEN, LEONIE; MAURER, DOMINIK; WALTER, STEFFEN; BUNK, SEBASTIAN
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 047924/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: ALTEN, LEONIE; MAURER, DOMINIK; WALTER, STEFFEN; BUNK, SEBASTIAN
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 043572/0045 →
Priority Claims (1)
DE 10 2016 115 246 · Aug 17, 2016 · national
Continuity (3)
Provisional Application 62376059 · Aug 17, 2016
Provisional Application 62376632 · Aug 18, 2016
Related Publication 20180051080A1 · Feb 22, 2018